Phillip Life Assurance Public Company Limited and its subsidiary Review report and interim financial information For the three-month period ended 31 March 2022



**EYOffice Limited** 

33rd Floor, Lake Rajada Office Complex 193/136-137 Rajadapisek Road Klongtoey, Bangkok 10110 Tel: +66 2264 9090

Fax: +66 2264 0789-90

ey.com

บริษัท สำนักงาน อีวาย จำกัด

ชั้น 33 อาการเลกรัชคา 193/136-137 ถนนรัชคาภิเมก คลองเตย กรุงเทพฯ 10110 โทรศัพท์: +66 2264 9090 โทรสาร: +66 2264 0789-90

ey.com

#### Independent Auditor's Report on Review of Interim Financial Information

To the Shareholders of Phillip Life Assurance Public Company Limited

I have reviewed the accompanying consolidated statement of financial position of Phillip Life Assurance Public Company Limited and its subsidiary as at 31 March 2022, and the related consolidated statements of comprehensive income, changes in owners' equity, and cash flows for the three-month period then ended, as well as the condensed notes to the interim consolidated financial statements. I have also reviewed the separate financial information of Phillip Life Assurance Public Company Limited for the same period (collectively called "interim financial information"). Management is responsible for the preparation and presentation of this interim financial information in accordance with Thai Accounting Standard 34 Interim Financial Reporting. My responsibility is to express a conclusion on this interim financial information based on my review.

#### Scope of Review

I conducted my review in accordance with Thai Standard on Review Engagements 2410, Review of Interim Financial Information Performed by the Independent Auditor of the Entity. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Thai Standards on Auditing and consequently does not enable me to obtain assurance that I would become aware of all significant matters that might be identified in an audit. Accordingly, I do not express an audit opinion.

#### Conclusion

Based on my review, nothing has come to my attention that causes me to believe that the accompanying interim financial information is not prepared, in all material respects, in accordance with Thai Accounting Standard 34 Interim Financial Reporting.



#### **Emphasis of Matter**

I draw attention to the matter as described in Note 2.1 to the interim financial statements that the volatilities in capital market and the fall of interest rates over the past several years pose difficulties for financial institutions in the market place. Adjustments have been made by companies to inject capital to meet the minimum prudential capital adequacy ratio ("CAR") of 140% as currently stipulated by the Office of the Insurance Commission ("the OIC"). As at 31 March 2022 the Company's CAR stood at 171% (based on management report, not yet reviewed or audited by the Company's auditor). However, the Company still plans to increase additional capital to support the continuing situation of the persistent low interest rate and the business expansion, and already executed its long-term plan by readjusting its product and investment strategies to enhance a sustainable efficiency in its business operation.

These market circumstances indicate uncertainties, which are dependent upon the success in achieving its capital increase plan and improving its operating performance. The major shareholder has been very supportive of all past capital calls and has undertaken to provide more capital if necessary to meet its growing policy commitments and the OIC's capital requirements. Furthermore, the major shareholder stated in its letter dated 16 March 2022 that it will provide financial support to the Company to enable it to maintain the CAR of not lower than the minimum requirement as stipulated by the OIC.

However, I have not modified my conclusion in respect of the above matter.

Rachada Yongsawadvanich

Certified Public Accountant (Thailand) No. 4951

EY Office Limited

h LL

Bangkok: 11 May 2022

# Phillip Life Assurance Public Company Limited and its subsidiary Statements of financial position

#### As at 31 March 2022 and 31 December 2021

(Unit: Baht)

		Consolidated fin	ancial statements	Separate finar	ncial statements
	Note	31 March 2022	31 December 2021	31 March 2022	31 December 2021
		(Unaudited but	(Audited)	(Unaudited but	(Audited)
		reviewed)		reviewed)	
Assets					
Cash and cash equivalents	3	582,885,163	516,913,634	577,376,373	511,089,117
Premium receivables	4	124,435,987	195,792,416	124,435,987	195,792,416
Accrued investment income		45,107,281	36,674,205	45,107,281	36,674,205
Reinsurance assets	5	8,755,320	8,601,145	8,755,320	8,601,145
Reinsurance receivables	6	5,669,565	5,911,231	5,669,565	5,911,231
Investment assets					
Investments in securities	7	12,653,360,604	12,679,539,156	12,653,360,604	12,679,539,156
Loans and interest receivables	8	886,463,707	901,559,801	886,463,707	901,559,801
Investments in a subsidiary	9	<del>u</del>	-	5,323,010	5,196,601
investment assets of the insured		231,235	248,369	231,235	248,369
Premises and equipment		191,880,540	200,040,024	191,880,540	200,040,024
Right-of-use assets	10.1	26,005,276	44,468,376	26,005,276	44,468,376
Intangible assets		6,326,551	7,388,302	6,326,551	7,388,302
Other assets	11	210,979,165	228,330,189	210,562,715	227,850,770
Total assets		14,742,100,394	14,825,466,848	14,741,498,164	14,824,359,513

The accompanying notes are an integral part of the financial statements.

Mary Committee of the c

# Phillip Life Assurance Public Company Limited and its subsidiary Statements of financial position (Continued)

As at 31 March 2022 and 31 December 2021

(Unit: Baht)

		Consolidated fin	anclai statements	Separate finar	ncial statements
	Note	31 March 2022	31 December 2021	31 March 2022	31 December 2021
		(Unaudited but reviewed)	(Audited)	(Unaudited but reviewed)	(Audited)
Liabilities and owners' equity					
Liabilities					
Insurance contract liabilities	12	10,145,545,199	10,658,574,723	10,145,545,199	10,658,574,723
Investment contract liabilities		231,235	248,369	231,235	248,369
Reinsurance payables	13	12,857,160	12,632,865	12,857,160	12,632,865
Lease liabilities	10.2	30,346,200	48,451,090	30,346,200	48,451,090
Employee benefit obligations		51,508,499	57,601,154	51,508,499	57,601,154
Deferred tax liabilities	14.1	184,269,085	200,790,907	184,269,085	200,790,907
Other liabilities	15	140,387,965	195,113,388	139,792,130	194,012,296
Total liabilities		10,565,145,343	11,173,412,496	10,564,549,508	11,172,311,404
Owners' equity					
Share capital					
Registered					
1,600 million ordinary shares of Baht 6.25 each		10,000,000,000	10,000,000,000	10,000;000,000	10,000,000,000
Issued and paid-up					
957.5 million ordinary shares of Baht 6.25 each		5,984,375,000	5,984,375,000	5,984,375,000	5,984,375,000
Share discount		(58,798,175)	(58,798,175)	(58,798,175)	(58,798,175)
Deficit		(2,397,045,406)	(2,923,809,405)	(2,397,045,406)	(2,923,809,405)
Other component of owners' equity					
Revaluation surplus on available-for-sale investment	S				
measured at fair value through other					
comprehensive income - net of income taxes	7.4	648,417,237	650,280,689	648,417,237	650,280,689
Equity attributable to equity holders of the Company		4,176,948,656	3,652,048,109	4,176,948,656	3,652,048,109
Non-controlling interests of the subsidiary		6,395	6,243		~
Total owners' equity		4,176,955,051	3,652,054,352	4,176,948,656	3,652,048,109
Total liabilities and owners' equity		14,742,100,394	14,825,466,848	14,741,498,164	14,824,359,513

The accompanying notes are an integral part of the financial statements.

Directors

# Phillip Life Assurance Public Company Limited and its subsidiary Statements of comprehensive income

For the three-month periods ended 31 March 2022 and 2021

(Unit: Baht)

Profit or loss:         2022         2021         2022         2021           Revenues         Revenues         868.351.886         810.814.423         868.351.886           Premium written         610.814.423         686.351.886         610.814.423         868.351.886           Less: Premium ceded to reinsurers         60.407.468         104.533.880         60.406.808         753.818.036           Less: Chearned premium riseerves Increased         169.449         4.428.2457         (194.449)         4.282.457           Ecres Unearned premium after reinsurance         60.431.2520         749.835.670         60.431.2520         749.835.670           Ecre and commission income         99.388         3.935.33         99.1386         3.935.33           Pace and commission income         60.431.2520         749.835.670         60.431.2520         749.835.670           Fea and commission income         60.431.2520         749.835.670         79.961.87         106.385.93         89.1386         3.935.38           Fea and commission income         60.431.2520         749.811.87         19.961.67         17.536.390         26.667.67         17.536.390         26.667.67         17.536.390         26.667.67         17.536.390         26.667.67         17.536.390         26.2667.67         17.536.390			Consolidated finar	ncial statements	Separate financ	ial statements
Revenues         Fremium written         610,814,423         858,351,896         810,814,423         858,351,896           Less: Premium odded to reinsurers         (6,307,454)         (104,533,860)         (6,307,454)         (104,533,860)         (6,307,454)         (104,533,860)         (6,307,454)         (104,533,860)         753,818,036         604,506,969         753,818,036         604,506,969         753,818,036         604,506,969         753,818,036         604,506,969         753,818,036         604,506,969         753,818,036         604,506,969         753,818,036         604,506,969         753,818,036         604,506,969         753,818,036         604,506,969         753,818,036         604,506,969         753,818,036         604,506,969         753,818,036         604,506,969         753,818,036         604,506,969         753,818,036         604,506,969         753,818,036         604,512,520         749,535,579         604,512,520         749,535,579         604,512,520         749,535,579         604,532,520         749,535,579         604,532,520         79,961,187         106,385,193         79,961,187         106,385,193         79,961,187         106,385,193         79,961,187         106,385,193         79,961,187         106,385,193         79,961,187         106,385,193         79,961,187         106,385,193         79,961,187         106,385,1		Note	2022	2021	2022	2021
Premium written         610,814,423         858,351,896         310,814,223         858,351,896           Less: Premium coded to reinsurers         (6,307,444)         (104,533,860)         (6,307,464)         (104,533,860)         (6,307,464)         (104,533,860)         73,818,036         804,506,069         753,818,036         804,506,069         753,818,036         804,506,069         753,818,036         804,506,069         753,818,036         804,506,069         753,818,036         804,506,069         753,818,036         804,506,069         753,818,036         804,506,069         753,818,036         804,506,069         753,818,036         804,506,069         753,818,036         804,506,069         753,818,036         804,506,069         753,818,036         804,506,069         753,818,036         804,506,069         753,818,036         804,507,569         749,555,579         604,312,520         749,555,579         604,312,520         749,555,579         604,312,520         749,555,579         804,312,520         749,555,579         804,312,520         749,555,579         804,533,833         891,386         3,935,383         891,386         3,935,383         891,386         3,935,383         891,386         40,541,525         80,541,518         60,451,525         80,451,525         80,451,525         80,451,525         80,451,525         80,451,525         8	Profit or loss:			ANI-TY-AR-LITE	***************************************	**************************************
Class: Premium ceded to reinsurers	Revenues					
Net premium written	Premium written		610,814,423	858,351,896	610,814,423	858,351,896
Class: Uneamed premium reserves increased from prior period (194,449) (4,282,457) (194,449) (4,282,457) (194,449) (4,282,457) (194,449) (4,282,457) (194,449) (1,282,457) (194,449) (1,282,457) (194,449) (1,282,457) (194,449) (1,282,457) (194,449) (1,282,457) (194,315,579) (194,315	Less: Premium ceded to reinsurers		(6,307,454)	(104,533,860)	(6,307,454)	(104,533,860)
from prior period         (194,449)         (4,282,457)         (194,449)         (4,282,457)         (194,449)         (4,282,457)         (2,282,457)	Net premium written		604,506,969	753,818,036	604,506,969	753,818,036
Earned premium affer reinsurance         604,312,520         749,535,579         604,312,520         749,535,579           Fee and commission income         991,386         3,935,383         991,386         3,935,883           Net investment revenues         79,961,187         106,385,193         79,961,187         106,385,193           Gain on investments         26,566,677         17,536,390         26,566,767         17,536,390           Fair value gains (losses)         (94,071,420)         64,541,268         (94,071,420)         64,541,268           Other income         653,271         532,936         364,681         421,978           Total revenues         618,413,711         942,466,739         618,251,529         942,343,493           Expenses         8         80,122,233         (601,202,337)         (799,134,293)         (601,202,337)         (799,134,293)           Unexpired risk reserves decreased from prior period         (801,202,337)         (789,134,293)         (601,202,337)         (799,134,293)           Unexpired risk reserves decreased from prior period         2,318,125         26,967,212         2,318,125         26,967,212           Eenefit payments under life policies and gross claims         592,279,679         714,443,053         592,279,679         714,443,053         192,276,738	Less: Unearned premium reserves increased					
Fee and commission income         991,386         3,935,383         991,386         3,935,383           Net investment revenues         79,961,187         106,385,193         79,961,187         106,385,193           Gain on investments         26,566,767         17,536,390         26,566,767         17,536,390           Fair value gains (losses)         (94,071,420)         64,541,258         (94,071,420)         64,541,258           Share of profit (loss) from investment in a subsidiary under equity method	from prior period		(194,449)	(4,282,457)	(194,449)	(4,282,457)
Net investment revenues         79,961,187         106,385,193         79,961,187         106,385,193           Gain on investments         26,566,767         17,536,390         26,566,767         17,536,390           Fair value gains (losses)         (94,071,420)         64,541,258         (94,071,420)         84,541,258           Share of profit (loss) from investment in a subsidiery under equity method         6         1         126,408         (12,288)           Other income         653,271         532,936         364,681         421,978           Total revenues         618,413,711         942,466,739         618,251,529         942,343,493           Unexpired risk reserves decreased from prior period         (601,202,337)         (799,134,293)         (601,202,337)         (799,134,293)           Unexpired risk reserves decreased from prior period         2,318,125         26,967,212         2,318,125         26,967,212           Benefit payments under life policies and gross claims         592,279,679         714,443,053         592,279,679         714,443,053         592,279,679         714,443,053         592,279,679         714,443,053         592,279,679         714,443,053         592,279,679         714,443,053         592,279,679         714,443,053         592,279,679         714,443,053         592,279,679         714,443,053 </td <td>Earned premium after reinsurance</td> <td></td> <td>604,312,520</td> <td>749,535,579</td> <td>604,312,520</td> <td>749,535,579</td>	Earned premium after reinsurance		604,312,520	749,535,579	604,312,520	749,535,579
Gain on investments         26,566,767         17,536,390         26,566,767         17,536,390           Fair value gains (losses)         (94,071,420)         64,541,258         (94,071,420)         64,541,258           Share of profit (loss) from investment in a subsidiary under equity method         2 - 126,408         126,408         12,288)           Other income         653,271         532,936         364,881         421,978           Total revenues         618,413,711         942,466,739         618,251,529         942,343,493           Expenses         Long-term life insurance policy reserves increased from prior period         (601,202,337)         (799,134,293)         (601,202,337)         (799,134,293)           Unexpired risk reserves decreased from prior period         2,318,125         26,967,212         2,318,125         26,967,212           Benefit payments under life policies and gross claims         592,279,879         714,443,053         592,279,679         714,443,053           Less: Benefit payments under life policies and gross claims         (2,276,738)         (132,352,542)         (2,276,738)         (132,352,542)           Commission and brokerage expenses         57,007,360         128,580,971         56,867,505         128,486,120           Other underwriting expenses         5,255,125         6,400,039         5,255,125 <td>Fee and commission income</td> <td></td> <td>991,386</td> <td>3,935,383</td> <td>991,386</td> <td>3,935,383</td>	Fee and commission income		991,386	3,935,383	991,386	3,935,383
Fair value gains (losses)         (94,071,420)         64,541,258         (94,071,420)         64,541,258           Share of profit (loss) from investment in a subsidiary under equity method         -         -         126,408         (12,288)           Other Income         653,271         532,936         364,681         421,978           Total revenues         618,413,711         942,466,739         618,251,529         942,343,493           Expenses         Long-term life insurance policy reserves increased from prior period         (601,202,337)         (799,134,293)         (601,202,337)         (799,134,293)           Unexpired risk reserves decreased from prior period         2,318,125         26,967,212         2,318,125         26,967,212           Benefit payments under life policies and gross claims         592,79,679         714,443,053         592,279,679         714,443,053           Less: Benefit payments under life policies and claims refundable from reinsurance         (2,276,738)         (132,352,542)         (2,276,738)         (132,352,542)           Commission and brokerage expenses         57,007,360         128,580,971         56,867,505         128,466,120           Other underwriting expenses         5,255,125         6,400,039         5,255,125         6,400,039           Finance costs         300,251         684,893	Net investment revenues		79,961,187	106,385,193	79,961,187	106,385,193
Share of profit (loss) from investment in a subsidiary under equity method         6         1         126,408         (12,288)           Other income         653,271         532,936         364,681         421,978           Total revenues         618,413,711         942,466,739         618,251,529         942,343,493           Expenses         8         8         8         8         8         8         8         942,343,493         (601,202,337)         (799,134,293)         (799,134,293)         (799,134,293)         (799,134,293)         (799,134,293)         (799,134,293)         (799,134,293)         (799,134,293)         (8         8         8         8         8         8         98,279,679         714,443,053         592,279,679         714,443,053         592,279,679         714,443,053         592,279,679         714,443,053         592,279,679         714,443,053         592,279,679         714,443,053         592,279,679         714,443,053         592,279,679         714,443,053         592,279,679         714,443,053         592,279,679         714,443,053         592,279,679         714,443,053         592,279,679         714,443,053         592,279,679         714,443,053         592,279,679         714,443,053         182,886,120         684,893         686,7505         128,886,120	Gain on investments		26,566,767	17,536,390	26,566,767	17,536,390
Under equily method         6.53,271         532,936         364,681         421,978           Total revenues         618,413,711         942,466,739         618,251,529         942,343,493           Expenses         Expenses         8.601,202,337         (799,134,293)         (601,202,337)         (799,134,293)         (601,202,337)         (799,134,293)         (799	Fair value gains (losses)		(94,071,420)	64,541,258	(94,071,420)	64,541,258
Other income         653,271         532,936         364,681         421,978           Total revenues         618,413,711         942,466,739         618,251,529         942,343,493           Expenses         Expenses         C799,134,293         (601,202,337)         (799,134,293)         (601,202,337)         (799,134,293)           Unexpired risk reserves decreased from prior period         2,318,125         26,967,212         2,318,125         26,967,212           Benefit payments under life policies and gross claims         592,279,679         714,443,053         592,279,679         714,443,053         592,279,679         714,443,053         592,279,679         714,443,053         128,580,971         66,867,505         128,486,120         (2,276,738)         (132,352,542)         (2,276,738)         (132,352,542)         6,400,039         5,255,125         6,400,039         5,255,125         6,400,039         5,255,125         6,400,039         5,255,125         6,400,039         5,255,125         6,400,039         5,255,125         6,400,039         5,255,125         6,400,039         5,255,125         6,400,039         5,255,125         6,400,039         5,255,125         6,400,039         5,255,125         6,400,039         6,526,045         9,400,039         6,526,045         9,400,039         6,526,045         9,400,049	Share of profit (loss) from investment in a subsidiary					
Total revenues         618,413,711         942,466,739         618,251,529         942,343,493           Expenses         Long-term life insurance policy reserves increased from prior period         (601,202,337)         (799,134,293)         (601,202,337)         (799,134,293)           Unexpired risk reserves decreased from prior period         2,318,125         26,967,212	under equity method		-	-	126,408	(12,288)
Expenses           Long-term life insurance policy reserves increased from prior period         (601,202,337)         (799,134,293)         (601,202,337)         (799,134,293)           Unexpired risk reserves decreased from prior period         2,318,125         26,967,212         2,318,125         26,967,212           Benefit payments under life policies and gross claims         592,279,679         714,443,053         592,279,679         714,443,053           Less: Benefit payments under life policies and claims refundable from reinsurance         (2,276,738)         (132,352,542)         (2,276,738)         (132,352,542)           Commission and brokerage expenses         57,007,360         128,580,971         56,867,505         128,486,120           Other underwriting expenses         5,255,125         6,400,039         5,255,125         6,400,039           Operating expenses         75,828,823         92,269,552         75,806,453         92,240,940           Finance costs         300,251         684,893         300,251         684,893           Expected credit losses (reversal)         16         (19,052,594)         15,798,846         (19,052,399)         15,799,049           Other expenses         1,010,016         24,072         1,010,016         24,072           Total expenses         506,946,001         88	Other income		653,271	532,936	364,681	421,978
Long-term life insurance policy reserves increased from prior period         (601,202,337)         (799,134,293)         (601,202,337)         (799,134,293)           Unexpired risk reserves decreased from prior period         2,318,125         26,967,212         2,318,125         26,967,212           Benefit payments under life policies and gross claims         592,279,679         714,443,053         592,279,679         714,443,053           Less: Benefit payments under life policies and claims refundable from reinsurance         (2,276,738)         (132,352,542)         (2,276,738)         (132,352,542)           Commission and brokerage expenses         57,007,360         128,580,971         56,867,505         128,486,120           Other underwriting expenses         5,255,125         6,400,039         5,255,125         6,400,039           Operating expenses         75,828,823         92,269,552         75,806,453         92,240,940           Finance costs         300,251         684,893         300,251         684,893           Expected credit losses (reversal)         16         (19,052,594)         15,798,846         (19,052,399)         15,799,049           Other expenses         1,010,016         24,072         1,010,016         24,072           Total expenses         506,946,001         888,784,936         506,945,849         8	Total revenues		618,413,711	942,466,739	618,251,529	942,343,493
Unexpired risk reserves decreased from prior period         2,318,125         26,967,212         2,318,125         26,967,212           Benefit payments under life policies and gross claims         592,279,679         714,443,053         592,279,679         714,443,053           Less: Benefit payments under life policies and claims refundable from reinsurance         (2,276,738)         (132,352,542)         (2,276,738)         (132,352,542)           Commission and brokerage expenses         57,007,360         128,580,971         56,867,505         128,486,120           Other underwriting expenses         5,255,125         6,400,039         5,255,125         8,400,039           Operating expenses         75,828,823         92,269,552         75,806,453         92,240,940           Finance costs         300,251         684,893         300,251         684,893           Expected credit losses (reversal)         16         (19,052,594)         15,798,846         (19,052,399)         15,799,049           Other expenses         1,010,016         24,072         1,010,016         24,072           Total expenses         111,467,710         53,681,803         111,305,680         53,558,543           Profit before income tax expenses         506,946,001         888,784,936         506,945,849         888,784,950 <t< td=""><td>Expenses</td><td></td><td></td><td></td><td></td><td></td></t<>	Expenses					
Benefit payments under life policies and gross claims         592,279,679         714,443,053         592,279,679         714,443,053           Less: Benefit payments under life policies and claims refundable from reinsurance         (2,276,738)         (132,352,542)         (2,276,738)         (132,352,542)           Commission and brokerage expenses         57,007,360         128,580,971         56,867,505         128,486,120           Other underwriting expenses         5,255,125         6,400,039         5,255,125         6,400,039           Operating expenses         75,828,823         92,269,552         75,806,453         92,240,940           Finance costs         300,251         684,893         300,251         684,893           Expected credit losses (reversal)         16         (19,052,594)         15,798,846         (19,052,399)         15,799,049           Other expenses         1,010,016         24,072         1,010,016         24,072           Total expenses         111,467,710         53,681,803         111,305,680         53,558,543           Profit before income tax expenses         506,946,001         888,784,936         506,945,849         888,784,950           Income tax benefits         14.2         16,055,959         733,677         16,055,959         733,677	Long-term life insurance policy reserves increased from prior	period	(601,202,337)	(799,134,293)	(601,202,337)	(799,134,293)
Less: Benefit payments under life policies and claims refundable from reinsurance       (2,276,738)       (132,352,542)       (2,276,738)       (132,352,542)         Commission and brokerage expenses       57,007,360       128,580,971       56,867,505       128,486,120         Other underwriting expenses       5,255,125       6,400,039       5,255,125       6,400,039         Operating expenses       75,828,823       92,269,552       75,806,453       92,240,940         Finance costs       300,251       684,893       300,251       684,893         Expected credit losses (reversal)       16       (19,052,594)       15,798,846       (19,052,399)       15,799,049         Other expenses       1,010,016       24,072       1,010,016       24,072         Total expenses       111,467,710       53,681,803       111,305,680       53,558,543         Profit before income tax expenses       506,946,001       888,784,936       506,945,849       888,784,950         Income tax benefits       14.2       16,055,959       733,677       16,055,959       733,677	Unexpired risk reserves decreased from prior period		2,318,125	26,967,212	2,318,125	26,967,212
claims refundable from reinsurance         (2,276,738)         (132,352,542)         (2,276,738)         (132,352,542)           Commission and brokerage expenses         57,007,360         128,580,971         56,867,505         128,486,120           Other underwriting expenses         5,255,125         6,400,039         5,255,125         6,400,039           Operating expenses         75,828,823         92,269,552         75,806,453         92,240,940           Finance costs         300,251         684,893         300,251         684,893           Expected credit losses (reversal)         16         (19,052,594)         15,798,846         (19,052,399)         15,799,049           Other expenses         1,010,016         24,072         1,010,016         24,072           Total expenses         111,467,710         53,681,803         111,305,680         53,558,543           Profit before income tax expenses         506,946,001         888,784,936         506,945,849         888,784,950           Income tax benefits         14.2         16,055,959         733,677         16,055,959         733,677	Benefit payments under life policies and gross claims		592,279,679	714,443,053	592,279,679	714,443,053
Commission and brokerage expenses         57,007,360         128,580,971         56,867,505         128,486,120           Other underwriting expenses         5,255,125         6,400,039         5,255,125         6,400,039           Operating expenses         75,828,823         92,269,552         75,806,453         92,240,940           Finance costs         300,251         684,893         300,251         684,893           Expected credit losses (reversal)         16         (19,052,594)         15,798,846         (19,052,399)         15,799,049           Other expenses         1,010,016         24,072         1,010,016         24,072           Total expenses         111,467,710         53,681,803         111,305,680         53,558,543           Profit before income tax expenses         506,946,001         888,784,936         506,945,849         888,784,950           Income tax benefits         14.2         16,055,959         733,677         16,055,959         733,677	Less: Benefit payments under life policies and					
Other underwriting expenses         5,255,125         6,400,039         5,255,125         6,400,039           Operating expenses         75,828,823         92,269,552         75,806,453         92,240,940           Finance costs         300,251         684,893         300,251         684,893           Expected credit losses (reversal)         16         (19,052,594)         15,798,846         (19,052,399)         15,799,049           Other expenses         1,010,016         24,072         1,010,016         24,072           Total expenses         111,467,710         53,681,803         111,305,680         53,558,543           Profit before income tax expenses         506,946,001         888,784,936         506,945,849         888,784,950           Income tax benefits         14.2         16,055,959         733,677         16,055,959         733,677	claims refundable from reinsurance		(2,276,738)	(132,352,542)	(2,276,738)	(132,352,542)
Operating expenses         75,828,823         92,269,552         75,806,453         92,240,940           Finance costs         300,251         684,893         300,251         684,893           Expected credit losses (reversal)         16         (19,052,594)         15,798,846         (19,052,399)         15,799,049           Other expenses         1,010,016         24,072         1,010,016         24,072           Total expenses         111,467,710         53,681,803         111,305,680         53,558,543           Profit before income tax expenses         506,946,001         888,784,936         506,945,849         888,784,950           Income tax benefits         14.2         16,055,959         733,677         16,055,959         733,677	Commission and brokerage expenses		57,007,360	128,580,971	56,867,505	128,486,120
Finance costs         300,251         684,893         300,251         684,893           Expected credit losses (reversal)         16         (19,052,594)         15,798,846         (19,052,399)         15,799,049           Other expenses         1,010,016         24,072         1,010,016         24,072           Total expenses         111,467,710         53,681,803         111,305,680         53,558,543           Profit before income tax expenses         506,946,001         888,784,936         506,945,849         888,784,950           Income tax benefits         14.2         16,055,959         733,677         16,055,959         733,677	Other underwriting expenses		5,255,125	6,400,039	5,255,125	6,400,039
Expected credit losses (reversal)         16         (19,052,594)         15,798,846         (19,052,399)         15,799,049           Other expenses         1,010,016         24,072         1,010,016         24,072           Total expenses         111,467,710         53,681,803         111,305,680         53,558,543           Profit before income tax expenses         506,946,001         888,784,936         506,945,849         888,784,950           Income tax benefits         14.2         16,055,959         733,677         16,055,959         733,677	Operating expenses		75,828,823	92,269,552	75,806,453	92,240,940
Other expenses         1,010,016         24,072         1,010,016         24,072           Total expenses         111,467,710         53,681,803         111,305,680         53,558,543           Profit before income tax expenses         506,946,001         888,784,936         506,945,849         888,784,950           Income tax benefits         14.2         16,055,959         733,677         16,055,959         733,677	Finance costs		300,251	684,893	300,251	684,893
Total expenses         111,467,710         53,681,803         111,305,680         53,558,543           Profit before income tax expenses         506,946,001         888,784,936         506,945,849         888,784,950           Income tax benefits         14.2         16,055,959         733,677         16,055,959         733,677	Expected credit losses (reversal)	16	(19,052,594)	15,798,846	(19,052,399)	15,799,049
Profit before income tax expenses         506,946,001         888,784,936         506,945,849         888,784,950           Income tax benefits         14.2         16,055,959         733,677         16,055,959         733,677	Other expenses		1,010,016	24,072	1,010,016	24,072
Income tax benefits 14.2 16,055,959 733,677 16,055,959 733,677	Total expenses		111,467,710	53,681,803	111,305,680	53,558,543
	Profit before income tax expenses		506,946,001	888,784,936	506,945,849	888,784,950
Net profit         523,001,960         889,518,613         523,001,808         889,518,627	Income tax benefits	14.2	16,055,959	733,677	16,055,959	733,677
	Net profit		523,001,960	889,518,613	523,001,808	889,518,627

The accompanying notes are an integral part of the financial statements.

Marsh Jan

#### Phillip Life Assurance Public Company Limited and its subsidiary

#### Statements of comprehensive income (Continued)

For the three-month periods ended 31 March 2022 and 2021

(Unit: Baht)

		Consolidated finan	ncial statements	Separate financi	al statements
	Note	2022	2021	2022	2021
Other comprehensive income (loss):					
Items to be recognised in profit or loss in subsequent period	ds:				
Gains (losses) on valuation of available-for-sale					
investments measured at fair value through other					
comprehensive income		(2,329,315)	37,284,517	(2,329,315)	37,284,517
Add (less): Income taxes	14.2	465,863	(7,456,903)	465,863	(7,456,903)
Items to be recognised in profit or loss in subsequent					
periods - net of Income taxes		(1,863,452)	29,827,614	(1,863,452)	29,827,614
Items not to be recognised in profit or loss in subsequent profit	eriods:		,		
Actuarial gains		3,762,191	-	3,762,191	-
Total items not to be recognised in profit or loss in subsequ	ent years	3,762,191	<del>-</del>	3,762,191	-
Other comprehensive income for the periods		1,898,739	29,827,614	1,898,739	29,827,614
Total comprehensive income for the periods		524,900,699	919,346,227	524,900,547	919,346,241
Net profit attributable to:					
The Company's shareholders		523,001,808	889,518,627	523,001,808	889,518,627
Non-controlling interests of the subsidiary		152	(14)		
		523,001,960	889,518,613		
Total comprehensive income for the periods attributab	le to:				
The Company's shareholders		524,900,547	919,346,241	524,900,547	919,346,241
Non-controlling interests of the subsidiary		152	(14)		
		524,900,699	919,346,227		
Basic earnings per share	17				
Earnings per share		0.55	0.96	0.55	0.96

The accompanying notes are an integral part of the financial statements.

I wil

(Unit: Baht)

Phillip Life Assurance Public Company Limited and its subsidiary

For the three-month periods ended 31 March 2022 and 2021

			သိ	Consolidated financial statements	ıts		
		Equity attribu	attributable to equity holders of the Company	rs of the Company		AND THE PROPERTY OF THE PROPER	
				Other component of equity	•		
				Revaluation surplus on			
			æ	available-for-sale investments			
				measured at fair	Total equity	Equity attributable	
	Issued and			value through other	attributable to	to non-controlling	
	dn-pad			comprehensive income	the Company's	interests of	
	share capital	Share discount	Deficit	- net of income taxes	shareholders	the subsidiary	Total
Balance as at 1 January 2021	5,684,375,000	(58,798,175)	(4,213,024,121)	550,291,946	1,962,844,650	6,085	1,962,850,735
Net profit		I	889,518,627		889,518,627	(14)	889,518,613
Other comprehensive income for the period	i	I	I	29,827,614	29,827,614	ı	29,827,614
Total comprehensive income for the period	ŧ	ı	889,518,627	29,827,614	919,346,241	(14)	919,346,227
Issuance of additional ordinary shares	300,000,000	ľ	I	ı	300,000,000	ŀ	300,000,000
Balance as at 31 March 2021	5,984,375,000	(58,798,175)	(3,323,505,494)	580,119,560	3,182,190,891	6,071	3,182,196,962
Balance as at 1 January 2022	5,984,375,000	(58,798,175)	(2,923,809,405)	650,280,689	3,652,048,109	6,243	3,652,054,352
Net profit	ı	-	523,001,808	J	523,001,808	152	523,001,960
Other comprehensive income (loss) for the period	1	*	3,762,191	(1,863,452)	1,898,739	ı	1,898,739
Total comprehensive income (loss) for the period	•	1	526,763,999	(1,863,452)	524,900,547	152	524,900,699
Balance as at 31 March 2022	5,984,375,000	(58,798,175)	(2,397,045,406)	648,417,237	4,176,948,656	6,395	4,176,955,051

The accompanying notes are an integral part of the financial statements.

The same of the sa

J.

Statements of changes in owners' equity

(Unit: Baht)

Phillip Life Assurance Public Company Limited and its subsidiary Statements of changes in owners' equity (Continued)

h 2022 and 2021	
31 March 2022 and	
the three-month periods ended 31 March	
hree-month p	
or the t	

			Separate financial statements	stements	
				Other component of equity	
				Revaluation surplus on	
				available-for-sale investments	
				measured at fair	
				value through other	
	Issued and			comprehensive income - net	
	paid-up share capital	Share discount	Deficit	of income taxes	Total
Balance as at 1 January 2021	5,684,375,000	(58,798,175)	(4,213,024,121)	. 550,291,946	1,962,844,650
Net profit		I	889,518,627	4	889,518,627
Other comprehensive income for the period	å	ı	ı	29,827,614	29,827,614
Total comprehensive income for the period	*	1	889,518,627	29,827,614	919,346,241
Issuance of additional ordinary shares	300,000,000	ı	ı		300,000,000
Balance as at 31 March 2021	5,984,375,000	(58,798,175)	(3,323,505,494)	580,119,560	3,182,190,891
	The state of the s	· · · · · · · · · · · · · · · · · · ·	- 1-d-rep-da Vol. martine de la constanta de l		i
Balance as at 1 January 2022	5,984,375,000	(58,798,175)	(2,923,809,405)	650,280,689	3,652,048,109
Net profit	,	1	523,001,808	•	523,001,808
Other comprehensive income (loss) for the period	ì	1	3,762,191	(1,863,452)	1,898,739
Total comprehensive income (loss) for the period		1	526,763,999	(1,863,452)	524,900,547
Balance as at 31 March 2022	5,984,375,000	(58,798,175)	(2,397,045,406)	648,417,237	4,176,948,656
				7	, and the second

The accompanying notes are an integral part of the financial statements.

#### Phillip Life Assurance Public Company Limited and its subsidiary

#### Statements of cash flows

For the three-month periods ended 31 March 2022 and 2021

(Unit: Baht)

Class Hows from (used in) operating activities         2021         2		Consolidated financial statements		Separate financial statements	
Gross premium from direct insurance         682,160,536         898,218,576         621,50,535         898,218,676           Cash paid from reinsurance         (2,573,369)         (12,004,994)         (2,573,369)         (12,004,994)           Interest Income         49,289,618         79,330,565         49,289,616         79,330,565           Dividend Income         18,914,184         21,533,820         18,914,184         21,533,820           Other income         9,768,708         532,936         9,480,117         421,979           Benefit payments under life policies and gross claims         (506,773,615)         (799,861,284)         (506,773,615)         (799,861,284)         (506,773,615)         (799,861,284)         (206,073,415)         (799,861,284)         (206,073,415)         (799,861,284)         (206,073,415)         (799,861,284)         (206,073,415)         (206,073,415)         (206,073,415)         (206,073,415)         (206,073,415)         (206,073,415)         (206,073,415)         (206,073,415)         (206,073,415)         (206,073,416)         (206,074,416)         (206,074,416)         (206,074,416)         (206,074,416)         (206,074,416)         (206,074,416)         (206,074,416)         (206,074,416)         (206,074,416)         (206,074,416)         (206,074,416)         (207,074,416)         (207,074,416)         (207,074,416)		2022	2021	2022	2021
Cash paid from reinsurance         (2,573,369)         (12,004,994)         (2,573,69)         (12,004,994)           Interest Income         49,289,618         79,330,665         49,289,616         79,330,565           Dividend Income         18,914,184         21,533,820         18,914,184         21,533,820           Other income         9,768,708         532,936         9,480,117         421,979           Benefit payments under life policies and gross claims         (506,773,615)         (799,861,284)         (506,773,615)         (799,861,284)           Commission and brokerage expenses on direct insurance         (64,156,035)         (206,009,343)         (64,016,180)         (205,914,492)           Other underwriting expenses         (6,848,310)         (6,895,480)         (6,848,310)         (62,693,977)         (75,652,605)           Operating expenses         (1,010,000)         (22,845)         (1,010,000)         (22,845)           Cash received on financial assets         (363,158,635)         (75,411,607)         (62,693,977)         (75,652,605)           Cash paid for financial assets         (384,880,711)         (12,206,454,823)         364,548,613         872,491,875           Ass provided by (used in) operating activities         71,670,981         (436,152,664)         71,966,903         (487,291)	Cash flows from (used in) operating activities				
Interest Income	Gross premium from direct insurance	682,150,535	898,218,576	682,150,535	898,218,576
Dividend Income         18,914,184         21,533,820         18,914,184         21,533,820           Other Income         9,768,708         532,936         9,480,117         421,979           Benefit payments under life policies and gross claims from direct insurance         (506,773,615)         (799,861,284)         (506,773,615)         (799,861,284)           Commission and brokerage expenses on direct insurance         (84,156,035)         (206,009,343)         (84,016,180)         (205,914,492)           Other underwriting expenses         (6,848,310)         (8,495,480)         (6,848,310)         (62,693,977)         (75,652,605)           Other expenses         (1,010,000)         (22,845)         (1,010,000)         (22,845)         (1,010,000)         (22,845)           Cash received on financial assets         (384,480,711)         (1,206,454,823)         364,548,613         872,491,875           Cash paid for financial assets         (384,480,711)         (1,206,454,823)         (388,480,711)         (1,206,454,823)           Net cash provided by (used in) operating activities         71,670,981         (438,152,664)         71,986,903         (436,409,708)           Cash flows from (used in) investing activities         371,072         (487,291)         371,072         (487,291)           Repayments of lease liabilities         (6	Cash paid from reinsurance	(2,573,369)	(12,004,994)	(2,573,369)	(12,004,994)
Other income         9,768,708         532,936         9,480,117         421,979           Benefit payments under life policies and gross claims from direct insurance         (506,773,615)         (799,861,284)         (506,773,615)         (799,861,284)           Commission and brokerage expenses on direct insurance         (84,156,035)         (206,009,343)         (84,016,180)         (205,914,492)           Other underwriting expenses         (6,848,310)         (8,495,480)         (6,848,310)         (8,495,480)           Operating expenses         (63,158,635)         (75,411,667)         (62,693,977)         (75,652,605)           Other expenses         (10,100,000)         (22,845)         (1,010,000)         (22,845)           Cash received on financial assets         (384,548,613)         872,491,875         364,548,613         872,491,875           Cash paid for financial assets         (388,480,711)         (1,206,454,623)         (388,480,711)         (1,206,454,823)           Net cash provided by (used in) operating activities         71,670,981         (487,291)         371,072         (487,291)           Requipment         371,072         (487,291)         371,072         (487,291)           Net cash provided by (used in) investing activities         (6,076,270)         (8,355,360)         (6,076,270)         (8,355,360)	Interest income	49,289,616	79,330,565	49,289,616	79,330,565
Benefit payments under life policies and gross claims           from direct insurance         (506,773,615)         (799,861,284)         (506,773,615)         (799,861,284)           Commission and brokerage expenses on direct insurance         (84,156,035)         (206,009,343)         (84,016,180)         (205,914,492)           Other underwriting expenses         (6,848,310)         (8,495,480)         (6,848,310)         (8,495,480)           Operating expenses         (63,158,635)         (75,411,667)         (62,693,977)         (75,652,605)           Other expenses         (1,010,000)         (22,845)         (1,010,000)         (22,845)           Cash received on financial assets         (388,480,711)         (1,206,454,823)         364,548,613         872,491,875           Cash paid for financial assets         (388,480,711)         (1,206,454,823)         (388,480,711)         (1,206,454,823)           Net cash provided by (used in) operating activities         71,670,981         (436,152,664)         71,986,903         (436,409,708)           Equipment         371,072         (487,291)         371,072         (487,291)           Net cash provided by (used in) investing activities         371,072         (487,291)         371,072         (487,291)           Cash flows from (used in) financial activities         (6,076,270)<	Dividend income	18,914,184	21,533,820	18,914,184	21,533,820
from direct insurance         (506,773,615)         (799,861,284)         (506,773,615)         (799,861,284)           Commission and brokerage expenses on direct insurance         (84,156,035)         (206,009,343)         (84,016,180)         (205,914,492)           Other underwriting expenses         (6,848,310)         (8,495,480)         (6,848,310)         (8,495,480)           Operating expenses         (63,158,635)         (75,411,667)         (62,693,977)         (75,652,605)           Other expenses         (1,010,000)         (22,845)         (1,010,000)         (22,845)           Cash received on financial assets         (384,480,711)         (1,206,454,823)         (388,480,711)         (1,206,454,823)           Cash paid for financial assets         (388,480,711)         (1,206,454,823)         (388,480,711)         (1,206,454,823)           Net cash provided by (used in) operating activities         71,670,981         (487,291)         371,072         (487,291)           Requipment         371,072         (487,291)         371,072         (487,291)           Net cash provided by (used in) investing activities         371,072         (487,291)         371,072         (487,291)           Repayments of lease liabilities         (6,076,270)         (8,355,360)         (6,076,270)         (8,355,360) <t< td=""><td>Other income</td><td>9,768,708</td><td>532,936</td><td>9,480,117</td><td>421,979</td></t<>	Other income	9,768,708	532,936	9,480,117	421,979
Commission and brokerage expenses on direct insurance         (84,156,035)         (206,009,343)         (84,016,180)         (205,914,492)           Other underwriting expenses         (6,848,310)         (8,495,480)         (6,848,310)         (8,495,480)           Operating expenses         (63,158,635)         (75,411,667)         (62,693,977)         (75,652,605)           Other expenses         (1,010,000)         (22,845)         (1,010,000)         (22,845)           Cash received on financial assets         384,548,613         872,491,875         364,548,613         872,491,875           Cash paid for financial assets         (388,480,711)         (1,206,454,823)         (388,480,711)         (1,206,454,823)           Net cash provided by (used in) operating activities         71,670,981         (436,152,664)         71,966,903         (436,409,708)           Cash flows from (used in) investing activities         371,072         (487,291)         371,072         (487,291)           Net cash provided by (used in) investing activities         (6,076,270)         (8,355,360)         (6,076,270)         (8,355,360)           Repayments of lease liabilities         (6,076,270)         (8,355,360)         (6,076,270)         291,644,640           Net cash provided by (used in) financing activities         (6,076,270)         291,644,640         (6,076	Benefit payments under life policies and gross claims				
Other underwriting expenses         (6,848,310)         (8,495,480)         (6,848,310)         (8,495,480)           Operating expenses         (63,158,635)         (75,411,667)         (62,693,977)         (75,652,605)           Other expenses         (1,010,000)         (22,845)         (1,010,000)         (22,845)           Cash received on financial assets         364,548,613         872,491,875         364,548,613         872,491,875           Cash paid for financial assets         (388,480,711)         (1,206,454,823)         (388,480,711)         (1,206,454,823)           Net cash provided by (used in) operating activities         71,670,981         (436,152,664)         71,986,903         (436,409,708)           Cash flows from (used in) investing activities         371,072         (487,291)         371,072         (487,291)           Net cash provided by (used in) investing activities         371,072         (487,291)         371,072         (487,291)           Cash flows from (used in) financial activities         (6,076,270)         (8,355,360)         (6,076,270)         (8,355,360)           Repayments of lease liabilities         (6,076,270)         (8,355,360)         (6,076,270)         291,644,640           Net cash provided by (used in) financing activities         (6,076,270)         291,644,640         (6,076,270)         29	from direct insurance	(506,773,615)	(799,861,284)	(506,773,615)	(799,861,284)
Operating expenses         (63,158,635)         (75,411,667)         (62,693,977)         (75,652,605)           Other expenses         (1,010,000)         (22,845)         (1,010,000)         (22,845)           Cash received on financial assets         364,548,613         872,491,875         364,548,613         872,491,875           Cash paid for financial assets         (388,480,711)         (1,206,454,823)         (388,480,711)         (1,206,454,823)           Net cash provided by (used in) operating activities         71,670,981         (436,152,664)         71,986,903         (436,409,708)           Equipment         371,072         (487,291)         371,072         (487,291)           Net cash provided by (used in) investing activities         371,072         (487,291)         371,072         (487,291)           Cash flows from (used in) financial activities         (6,076,270)         (8,355,360)         (6,076,270)         (8,355,360)           Proceeds from issuance of additional ordinary shares         - 300,000,000         - 300,000,000         - 300,000,000           Net cash provided by (used in) financing activities         (6,076,270)         291,644,640         (6,076,270)         291,644,640           Net increase (decrease) in cash and cash equivalents         65,965,783         (144,995,315)         66,281,705         (145,252,359) <td>Commission and brokerage expenses on direct insurance</td> <td>(84,156,035)</td> <td>(206,009,343)</td> <td>(84,016,180)</td> <td>(205,914,492)</td>	Commission and brokerage expenses on direct insurance	(84,156,035)	(206,009,343)	(84,016,180)	(205,914,492)
Other expenses         (1,010,000)         (22,845)         (1,010,000)         (22,845)           Cash received on financial assets         364,548,613         872,491,875         364,548,613         872,491,875           Cash paid for financial assets         (388,480,711)         (1,206,454,823)         (388,480,711)         (1,206,454,823)           Net cash provided by (used in) operating activities         71,670,981         (436,152,664)         71,986,903         (436,409,708)           Equipment         371,072         (487,291)         371,072         (487,291)           Net cash provided by (used in) investing activities         371,072         (487,291)         371,072         (487,291)           Cash flows from (used in) financial activities         (6,076,270)         (8,355,360)         (6,076,270)         (8,355,360)           Proceeds from issuance of additional ordinary shares         - 300,000,000         - 300,000,000         - 300,000,000           Net cash provided by (used in) financing activities         (6,076,270)         291,644,640         (6,076,270)         291,644,640           Net increase (decrease) in cash and cash equivalents         65,965,783         (144,995,315)         66,281,705         (145,252,359)           (Increase) decrease in allowance for expected credit losses         5,746         (98,375)         5,551	Other underwriting expenses	(6,848,310)	(8,495,480)	(6,848,310)	(8,495,480)
Cash received on financial assets         364,548,613         872,491,875         364,548,613         872,491,875           Cash paid for financial assets         (388,480,711)         (1,206,454,823)         (388,480,711)         (1,206,454,823)           Net cash provided by (used in) operating activities         71,670,981         (436,152,664)         71,986,903         (436,409,708)           Cash flows from (used in) investing activities         371,072         (487,291)         371,072         (487,291)           Net cash provided by (used in) investing activities         371,072         (487,291)         371,072         (487,291)           Cash flows from (used in) financial activities         (6,076,270)         (8,355,360)         (6,076,270)         (8,355,360)           Proceeds from issuance of additional ordinary shares         - 300,000,000         - 300,000,000         300,000,000           Net cash provided by (used in) financing activities         (6,076,270)         291,644,640         (6,076,270)         291,644,640           Net increase (decrease) in cash and cash equivalents         65,965,783         (144,995,315)         66,281,705         (145,252,359)           (Increase) decrease in allowance for expected credit losses         5,746         (98,375)         5,551         (98,578)           Cash and cash equivalents at beginning of the periods         51	Operating expenses	(63,158,635)	(75,411,667)	(62,693,977)	(75,652,605)
Cash paid for financial assets         (388,480,711)         (1,206,454,823)         (388,480,711)         (1,206,454,823)           Net cash provided by (used in) operating activities         71,670,981         (436,152,664)         71,986,903         (436,409,708)           Cash flows from (used in) investing activities         371,072         (487,291)         371,072         (487,291)           Net cash provided by (used in) investing activities         371,072         (487,291)         371,072         (487,291)           Cash flows from (used in) financial activities         (6,076,270)         (8,355,360)         (6,076,270)         (8,355,360)           Proceeds from issuance of additional ordinary shares         300,000,000         300,000,000         300,000,000           Net cash provided by (used in) financing activities         (6,076,270)         291,644,640         (6,076,270)         291,644,640           Net increase (decrease) in cash and cash equivalents         65,965,783         (144,995,315)         66,281,705         (145,262,359)           (Increase) decrease in allowance for expected credit losses         5,746         (98,375)         5,551         (98,578)           Cash and cash equivalents at beginning of the periods         516,913,634         356,875,004         511,089,117         351,883,915	Other expenses	(1,010,000)	(22,845)	(1,010,000)	(22,845)
Net cash provided by (used in) operating activities         71,670,981         (436,152,664)         71,986,903         (436,409,708)           Cash flows from (used in) investing activities         371,072         (487,291)         371,072         (487,291)           Net cash provided by (used in) investing activities         371,072         (487,291)         371,072         (487,291)           Cash flows from (used in) financial activities         (6,076,270)         (8,355,360)         (6,076,270)         (8,355,360)           Proceeds from issuance of additional ordinary shares         - 300,000,000         - 300,000,000         300,000,000           Net cash provided by (used in) financing activities         (6,076,270)         291,644,640         (6,076,270)         291,644,640           Net increase (decrease) in cash and cash equivalents         65,965,783         (144,995,315)         66,281,705         (145,252,359)           (Increase) decrease in allowance for expected credit losses         5,746         (98,375)         5,551         (98,578)           Cash and cash equivalents at beginning of the periods         516,913,634         356,875,004         511,089,117         351,883,915	Cash received on financial assets	364,548,613	872,491,875	364,548,613	872,491,875
Cash flows from (used in) Investing activities           Equipment         371,072         (487,291)         371,072         (487,291)           Net cash provided by (used in) Investing activities         371,072         (487,291)         371,072         (487,291)           Cash flows from (used in) financial activities         Repayments of lease liabilities           Repayments of lease liabilities         (6,076,270)         (8,355,360)         (6,076,270)         (8,355,360)           Proceeds from issuance of additional ordinary shares         -         300,000,000         -         300,000,000           Net cash provided by (used in) financing activities         (6,076,270)         291,644,640         (6,076,270)         291,644,640           Net increase (decrease) in cash and cash equivalents         65,965,783         (144,995,315)         66,281,705         (145,252,359)           (Increase) decrease in allowance for expected credit losses         5,746         (98,375)         5,551         (98,578)           Cash and cash equivalents at beginning of the periods         516,913,634         356,875,004         511,089,117         351,883,915	Cash paid for financial assets	(388,480,711)	(1,206,454,823)	(388,480,711)	(1,206,454,823)
Equipment         371,072         (487,291)         371,072         (487,291)           Net cash provided by (used in) investing activities         371,072         (487,291)         371,072         (487,291)           Cash flows from (used in) financial activities         (6,076,270)         (8,355,360)         (6,076,270)         (8,355,360)           Proceeds from issuance of additional ordinary shares         - 300,000,000         - 300,000,000           Net cash provided by (used in) financing activities         (6,076,270)         291,644,640         (6,076,270)         291,644,640           Net increase (decrease) in cash and cash equivalents         65,965,783         (144,995,315)         66,281,705         (145,252,359)           (Increase) decrease in allowance for expected credit losses         5,746         (98,375)         5,551         (98,578)           Cash and cash equivalents at beginning of the periods         516,913,634         356,875,004         511,089,117         351,883,915	Net cash provided by (used in) operating activities	71,670,981	(436,152,664)	71,986,903	(436,409,708)
Net cash provided by (used in) Investing activities         371,072         (487,291)         371,072         (487,291)           Cash flows from (used in) financial activities         Repayments of lease liabilities         (6,076,270)         (8,355,360)         (6,076,270)         (8,355,360)           Proceeds from issuance of additional ordinary shares         - 300,000,000         - 300,000,000         - 300,000,000         - 300,000,000           Net cash provided by (used in) financing activities         (6,076,270)         291,644,640         (6,076,270)         291,644,640         (6,076,270)         291,644,640         (6,076,270)         291,644,640         (6,076,270)         291,644,640         (6,076,270)         291,644,640         (6,076,270)         291,644,640         (6,076,270)         291,644,640         (6,076,270)         291,644,640         (6,076,270)         291,644,640         (6,076,270)         291,644,640         (6,076,270)         291,644,640         (6,076,270)         291,644,640         (6,076,270)         291,644,640         (6,076,270)         291,644,640 <td< td=""><td>Cash flows from (used in) investing activities</td><td></td><td></td><td></td><td></td></td<>	Cash flows from (used in) investing activities				
Cash flows from (used in) financial activities         Repayments of lease liabilities       (6,076,270)       (8,355,360)       (6,076,270)       (8,355,360)         Proceeds from issuance of additional ordinary shares       - 300,000,000       - 300,000,000         Net cash provided by (used in) financing activities       (6,076,270)       291,644,640       (6,076,270)       291,644,640         Net increase (decrease) in cash and cash equivalents       65,965,783       (144,995,315)       66,281,705       (145,252,359)         (Increase) decrease in allowance for expected credit losses       5,746       (98,375)       5,551       (98,578)         Cash and cash equivalents at beginning of the periods       516,913,634       356,875,004       511,089,117       351,883,915	Equipment	371,072	(487,291)	371,072	(487,291)
Repayments of lease liabilities         (6,076,270)         (8,355,360)         (6,076,270)         (8,355,360)           Proceeds from issuance of additional ordinary shares         -         300,000,000         -         300,000,000           Net cash provided by (used in) financing activities         (6,076,270)         291,644,640         (6,076,270)         291,644,640           Net increase (decrease) in cash and cash equivalents         65,965,783         (144,995,315)         66,281,705         (145,252,359)           (Increase) decrease in allowance for expected credit losses         5,746         (98,375)         5,551         (98,578)           Cash and cash equivalents at beginning of the periods         516,913,634         356,875,004         511,089,117         351,883,915	Net cash provided by (used in) investing activities	371,072	(487,291)	371,072	(487,291)
Proceeds from issuance of additional ordinary shares - 300,000,000 - 300,000,000  Net cash provided by (used in) financing activities (6,076,270) 291,644,640 (6,076,270) 291,644,640  Net increase (decrease) in cash and cash equivalents 65,965,783 (144,995,315) 66,281,705 (145,252,359) (Increase) decrease in allowance for expected credit losses 5,746 (98,375) 5,551 (98,578)  Cash and cash equivalents at beginning of the periods 516,913,634 356,875,004 511,089,117 351,883,915	Cash flows from (used in) financial activities				
Net cash provided by (used in) financing activities         (6,076,270)         291,644,640         (6,076,270)         291,644,640           Net increase (decrease) in cash and cash equivalents         65,965,783         (144,995,315)         66,281,705         (145,252,359)           (Increase) decrease in allowance for expected credit losses         5,746         (98,375)         5,551         (98,578)           Cash and cash equivalents at beginning of the periods         516,913,634         356,875,004         511,089,117         351,883,915	Repayments of lease liabilities	(6,076,270)	(8,355,360)	(6,076,270)	(8,355,360)
Net increase (decrease) in cash and cash equivalents         65,965,783         (144,995,315)         66,281,705         (145,252,359)           (Increase) decrease in allowance for expected credit losses         5,746         (98,375)         5,551         (98,578)           Cash and cash equivalents at beginning of the periods         516,913,634         356,875,004         511,089,117         351,883,915	Proceeds from issuance of additional ordinary shares		300,000,000	-	300,000,000
(Increase) decrease in allowance for expected credit losses 5,746 (98,375) 5,551 (98,578)  Cash and cash equivalents at beginning of the periods 516,913,634 356,875,004 511,089,117 351,883,915	Net cash provided by (used in) financing activities	(6,076,270)	291,644,640	(6,076,270)	291,644,640
Cash and cash equivalents at beginning of the periods 516,913,634 356,875,004 511,089,117 351,883,915	Net increase (decrease) in cash and cash equivalents	65,965,783	(144,995,315)	66,281,705	(145,252,359)
Cash and cash equivalents at beginning of the periods	(Increase) decrease in allowance for expected credit losses	5,746	(98,375)	5,551	(98,578)
Cash and cash equivalents at end of the periods 582,885,163 211,781,314 577,376,373 206,532,978	Cash and cash equivalents at beginning of the periods	516,913,634	356,875,004	511,089,117	351,883,915
	Cash and cash equivalents at end of the periods	582,885,163	211,781,314	577,376,373	206,532,978

The accompanying notes are an integral part of the financial statements.

mel M

# Phillip Life Assurance Public Company Limited and its subsidiary Table of contents for notes to interim financial statements For the three-month periods ended 31 March 2022 and 2021

Note	e Content	Page
1.	General information	1
2.	Basis of preparation of interim financial information	1
3.	Cash and cash equivalents	4
4.	Premium receivables	4
5.	Reinsurance assets	5
6.	Reinsurance receivables	5
7.	Investments in securities	6
8.	Loans and interest receivables	
9.	Investment in a subsidiary	12
10.	Leases	
11.	Other assets	13
12.	Insurance contract liabilities	14
13.	Reinsurance payables	
14.	Deferred tax liabilities and income tax benefits	18
15.	Other liabilities	
16.	Expected credit losses	22
17.	Earnings per share	
18.	Related party transactions	23
19.	Litigations	
20.	Fair values of financial instruments	
21.	Approval of interim financial information	29

Phillip Life Assurance Public Company Limited

Notes to interim financial statements

For the three-month periods ended 31 March 2022 and 2021

#### 1. General information

#### 1.1 Corporate information

Phillip Life Assurance Public Company Limited (the "Company") was established as a public company under Thai laws and domiciled in Thailand. As at 31 March 2022 and 31 December 2021, major shareholder is Phillip Life Company Limited, which was incorporated in Singapore, holding 99.79% and 99.79%, respectively, of the issued and paid-up share capital of the Company.

The Company is principally engaged in the provision of life insurance services. The registered office of the Company is located at No. 849, Vorawat Building, Silom Road, Silom Sub-district, Bangrak District, Bangkok. As of 31 March 2022 and 31 December 2021, the Company had altogether 18 branches, and 24 branches, respectively.

#### 1.2 The Coronavirus 2019 pandemic

The Coronavirus 2019 (COVID-19) pandemic results in an economic slowdown and impacts businesses and industries in various sectors. This situation may bring uncertainties and have an impact on the environment in which the business operates. The Company's management has continuously monitored ongoing developments and assessed the financial impact in respect of the valuation of assets, provisions and contingent liabilities, and has used estimates and judgement in respect of various issues (if any) as the situation has evolved.

## 2. Basis of preparation of interim financial information

#### 2.1 Accounting assumption

The volatilities in capital market and the fall of interest rates over the past several years pose difficulties for financial institutions in the market place. Adjustments have been made by companies to inject capital to meet the minimum prudential capital adequacy ratio ("CAR") of 140% as currently stipulated by the Office of the Insurance Commission ("the OIC"). As at 31 March 2022, the Company's CAR stood at 171% (based on management report, not yet reviewed or audited by the Company's auditor). However, the Company still plans to increase additional capital to support the continuing situation of the persistent low interest rate and the business expansion, and already executed its long-term plan by readjusting its product and investment strategies to enhance a sustainable efficiency in its business operation.

These market circumstances indicate uncertainties, which are dependent upon the success in achieving its capital increase plan an improving its operating performance. The major shareholder has been very supportive of all past capital calls and has undertaken to provide more capital if necessary, to meet its growing policy commitments and the OIC's capital requirements. Furthermore, the major shareholder stated in its letter dated 16 March 2022 that it will provide financial support to the Company to enable it to maintain the CAR of not lower than the minimum requirement as stipulated by the OIC.

With the above plans, the Company's management believes that the Company would be able to operate an on-going business and these financial statements were therefore prepared under the going concern assumptions, with assets and liabilities carried on the basis that the Company will be able to realise assets and settle liabilities in the normal course of business.

#### 2.2 Basis of preparation of interim financial information

This interim financial information is prepared in accordance with Thai Accounting Standard 34 Interim Financial Reporting, with the Company choosing to present condensed interim financial statements. However, the Company presented each line item in the statements of financial position, comprehensive income, changes in owners' equity and cash flows in the same full format as that used in preparation of its annual financial statements and in accordance with the format of financial statements specified in the Notification of the Office of Insurance Commission regarding criteria, procedures, terms and conditions for preparation and submission of financial statements and operating performance reports of life insurance companies (No. 2) B.E. 2562 dated 4 April 2019.

This interim financial information is intended to provide information additional to that included in the latest annual financial statements. Accordingly, they focus on new activities, events and circumstances so as not to duplicate information previously reported. This interim financial information should therefore be read in conjunction with the latest annual financial statements.

The interim financial information in Thai language is the official interim statutory financial information of the Company. The interim financial information in English language has been translated from such interim financial information in Thai language.

#### 2.3 Basis of consolidation

(a) The consolidated financial statements include the financial statements of Phillip Life Assurance Public Company Limited ("the Company") and the following subsidiary (collectively called "the Group").

		Country of		
Company's name	Nature of business	incorporation	Percentage of	of shareholding
			31 March 2022	31 December 2021
			(Percent)	(Percent)
Phillip Insurance Broker	Non-life insurance broker	Thailand	99.88	99.88
Company Limited				

- (b) Subsidiary is fully consolidated, being the date on which the Company obtains control, and continue to be consolidated until the date when such control ceases.
- (c) The financial statements of the subsidiary are prepared using the same significant accounting policies as the Company.
- (d) Material balances and transactions between the Group have been eliminated from the consolidated financial statements.
- (e) Non-controlling interests represent the portion of profit or loss and net assets of the subsidiary that are not held by the Company and are presented separately in the consolidated profit or loss and within equity in the consolidated statement of financial position.

#### 2.4 Separate financial statements

The Company has prepared its separate financial statements, which have presented investment in a subsidiary under the equity method.

#### 2.5 New financial reporting standards

The revised financial reporting standards, which are effective for fiscal years beginning on or after 1 January 2022, do not have any significant impact on the Company's financial statements.

However, the Company applied the temporary exemption for the adoption of Thai Financial Reporting Standard 9 (TFRS 9): Financial Instruments and Thai Financial Reporting Standard 7 (TFRS 7): Disclosure of Information relating to Financial Instruments, which were revised in Thai Financial Reporting Standard 4: Insurance Contracts allowing the extension of the exemption period for the adoption of such TFRS 9 and TFRS 4 whereby the exemption period will end for the financial statements having the fiscal period starts on or after 1 January 2024 or when Thai Financial Reporting Standard 17: Insurances Contracts becomes effective.

#### 2.6 Significant accounting policies

This interim financial information is prepared using the same significant accounting policies and methods of computation as those were used for preparation the financial statements for the year ended 31 December 2021.

#### 3. Cash and cash equivalents

			(Unit: Thousand baht)	
	Cons	olidated	Sep	arate
	financial	statements	financial s	statements
-	31 March	31 December	31 March	31 December
	2022	2021	2022	2021
Cash on hand	105	284	105	284
Deposits at banks with no fixed maturity date	582,975	456,846	577,463	451,018
Investments with maturity periods of not				
longer than 3 months	-	59,973	_	59,973
Total cash and cash equivalents	583,080	517,103	577,568	511,275
Less: Allowance for expected credit losses	(195)	(189)	(192)	(186)
Cash and cash equivalents - net	582,885	516,914	577,376	511,089

#### 4. Premium receivables

As at 31 March 2022 and 31 December 2021, the outstanding balances of premium receivables, classified by overdue periods, counted from the grace-period due dates, were as follows:

(Unit: Thousand baht)
Consolidated and separate

financial statements

	31 March 2022	31 December 2021
Not yet due	124,395	195,752
Not over 30 days	3	3
Over 31 days to 60 days	5	-
Over 61 days to 90 days	-	1
Overdue longer than 90 days	5,883	5,906
Total premium receivables	130,286	201,662
Less: Allowance for doubtful accounts	(5,850)	(5,870)
Premium receivables - net	124,436	195,792

#### 5. Reinsurance assets

As at 31 March 2022 and 31 December 2021, reinsurance assets consisted of reserves refundable from reinsurers as follows:

(Unit: Thousand baht)

Consolidated and separate

	financial statements		
	31 March 2022	31 December 2021	
Insurance reserve refundable from reinsurers			
Unearned premium reserves	8,262	7,910	
Unexpired Risk Reserves	243	299	
Loss reserves			
Claims incurred and reported	203	269	
Claims incurred but not yet reported	47	123	
Reinsurance assets	8,755	8,601	

#### 6. Reinsurance receivables

As at 31 March 2022 and 31 December 2021, reinsurance receivables consisted of the following:

(Unit: Thousand baht)

Consolidated and separate

	financial	financial statements				
	31 March 2022	31 December 2021				
Amounts due from reinsurers	5,670	5,911				
Reinsurance receivables	5,670	5,911				

#### 7. Investments in securities

## 7.1 Classified by investment type

	Consolidated and separate financial statements					
	31 Marcl	า 2022	31 Decemb	per 2021		
	Cost/		Cost/			
	Amortised cost	Fair value	Amortised cost	Fair value		
Tue dimenting a description of the fair						
Trading investments measured at fair						
value through profit or loss	2 227 747	0.440.000	0.00E.0E4	2 457 049		
Domestic unit trusts	3,337,747	3,449,222	3,265,951	3,457,912		
Foreign unit trusts	616,033	663,964	611,091	662,619		
Total	3,953,780	4,113,186	3,877,042	4,120,531		
Add : Revaluation allowance						
from fair value measurement	111,309		191,451			
from translation of foreign currencies	48,097		52,038			
Total revaluation allowance	159,406		243,489			
Trading investments measured at fair						
value through profit or loss - net	4,113,186		4,120,531			
Available-for-sale investments						
measured at fair value through other						
comprehensive income						
Government and state enterprise securities	2,042,251	2,007,700	1,992,011	2,026,196		
Private sector debt securities	2,796,355	2,811,241	2,807,180	2,867,378		
Domestic common stocks	404,460	437,482	453,644	505,829		
Foreign common stocks	1,386,732	2,159,675	1,386,731	2,060,621		
Domestic unit trusts	865,413	837,708	860,974	818,191		
Foreign unit trusts	227,015	266,052	227,015	260,623		
Total	7,722,226	8,519,858	7,727,555	8,538,838		
Add: Revaluation allowance						
from fair value measurement	810,521		812,840			
from translation of foreign currencies	100,356		110,345			
Total revaluation allowance	910,877		923,185			
Less: Allowance for impairment	(20,101)		(18,872)			
Less: Allowance for expected credit losses	(93,144)		(93,030)			
Available-for-sale investments measured at						
fair value through other comprehensive						
income - net	8,519,858		8,538,838			

(Unit: Thousand baht)

	Consol	dated and sepa	arate financial statements			
	31 Marc	h 2022	31 December 2021			
	Cost/		Cost/			
	Amortised cost	Fair value	Amortised cost	Fair value		
Held-to-maturity investments						
measured at amortised cost						
Deposits at financial institutions with						
maturity period of longer than 3 months	20,317		20,170			
Less: Allowance for expected credit						
losses						
Held-to-maturity investments measured						
at amortised cost - net	20,317		20,170			
Investments in securities - net	12,653,361		12,679,539			

## 7.2 Classified by stage of credit risk

_	Consolidated and separate financial statements						
_	31 Mar	ch 2022	31 December 2021				
		Allowance for expected credit		Allowance for expected credit			
-	Fair value	losses	Fair value	losses			
Available-for-sale investments measured at fair value through other comprehensive income Stage 1 - Debt securities without a							
significant increase of credit risk	5,004,073	(4,064)	5,073,277	(3,950)			
Stage 3 - Credit - Impaired debt							
securities	80,920	(89,090)	80,920	(89,080)			
Total	5,084,993	(93,144)	5,154,197	(93,030)			

			(Unit: Thousand baht)		
	Consolidate	d and separate financ	cial statements		
_		31 March 2022			
		Allowance for			
	Gross	expected credit	Net		
	carrying value	losses	carrying value		
Held-to-maturity investments measured					
at amortised cost					
Stage 1 - Debt securities without a significant					
increase of credit risk	20,317	_	20,317		
Total	20,317		20,317		
			(Unit: Thousand baht)		
_	Consolidate	d and separate financ	cial statements		
·	31 December 2021				
		Allowance for	•		
	Gross	expected credit	Net		

losses

### Held-to-maturity investments measured at amortised cost

Stage 1 - Debt securities without a significant

increase of credit risk	20,170	-
Total	20,170	-

carrying value

carrying value

20,170

20,170

## 7.3 Investments subject to restrictions

As at 31 March 2022 and 31 December 2021, the Group placed certain assets as securities and insurance reserves as described below.

(Unit: Thousand baht)

	Consolidated and separate financial statements					
	31 Marc	h 2022	31 December 2021			
	Amortised cost	Fair value	Amortised cost	Fair value		
Placed with the Life Assurance Regis	strar:					
As securities	22,640	22,336	22,705	23,170		
As life insurance reserves	2,452,440	2,457,368	2,402,292	2,481,417		
Total	2,475,080	2,479,704	2,424,997	2,504,587		
Placed with bank:						
As securities	20,317	20,317	20,170	20,170		

# 7.4 Revaluation surplus on available-for-sale investments measured at fair value through other comprehensive income

	Consolidated and separate financial staten			
	For the three-month	For the		
	period ended	year ended		
	31 March 2022	31 December 2021		
Balances at beginning of the periods	812,851	687,865		
Gains on revaluation during the periods	23,312	251,927		
Recognition of expected credit losses in profit or loss	114	(73)		
Recognition (reversal) of impairment loss in profit or loss	1,229	(7,965)		
Recognition of losses on sales in profit or loss	(26,985)	(118,903)		
Balances at end of the periods	810,521	812,851		
Less: Income taxes	(162,104)	(162,570)		
Balances at end of the periods - net of income taxes	648,417	650,281		

#### 8. Loans and interest receivables

# 8.1 Loans and interest receivables classified by overdue periods

As at 31 March 2022 and 31 December 2021, the balances of loans and interest receivables classified by overdue periods of principal and interest receivables were as follows:

(Unit: Thousand baht)

	Consolidated and separate financial statements										
	31 March 2022										
	Polic	y loans	Mortga	Mortgage loans		r Ioans		Total			
		Interest		Interest		Interest		Interest			
Overdue periods	Principal	receivables	Principal	receivables	Principal	receivables	Principal	receivables	Total		
Not yet due	531,005	16,527	71,599	594	60	•	602,664	17,121	619,785		
Past due											
Less than 3 months	•	-	3,278	4	-	-	3,278	4	3,282		
3 - 6 months	-	-	8,148	69	-	-	8,148	69	8,217		
6 - 12 months	-		23,303	456	-	-	23,303	456	23,759		
Over 12 months			433,208	69,762		-	433,208	69,762	502,970		
Total	531,005	16,527	539,536	70,885	60	_	1,070,601	87,412	1,158,013		
Less: Allowance for											
expected credit losses	_	*	(241,754)	(29,795)	. +		(241,754)	(29,795)	(271,549)		
Loans and interest											
recelvables - net	531,005	16,527	297,782	41,090	60	-	828,847	57,617	886,464		

			C	Consolidated an	d separate fina	ancial statemer	ts			
	31 December 2021									
	Polic	/ loans	Mortgag	ge loans	Other	loans		Total		
		Interest		Interest		Interest		Interest		
Overdue periods	Principal	recelvables	Principal	receivables	Principal	receivables	Principal	receivables	Total	
Not yet due	538,713	16,128	65,868	594	58	-	604,639	16,722	621,361	
Past due										
Less than 3 months	-	-	12,455	5	-	•	12,455	5	12,460	
3 - 6 months	-	-	31,303	356	-		31,303	356	31,659	
6 - 12 months	-		213	20	-	-	213	20	233	
Over 12 months			463,269	64,197	_	-	463,269	64,197	527,466	
Total	538,713	16,128	573,108	65,172	58	-	1,111,879	81,300	1,193,179	
Less: Allowance for										
expected credit losses		+	(262,133)	(29,486)		-	(262,133)	(29,486)	(291,619)	
Loans and Interest										
receivables - net	538,713	16,128	310,975	35,686	58	-	849,746	51,814	901,560	

As at 31 March 2022 and 31 December 2021, mortgage loans were loans provided to agents, employees and external individuals on which interest was charged at the rates between 5 to 19 percent per annum. Collateral used to secure such loans comprised land and buildings.

As at 31 March 2022 and 31 December 2021, other loans were loans provided to employees and agents, which were guaranteed by personal guarantees or motor vehicles and on which interest was charged at the rates between 7 percent per annum.

#### 8.2 Loans and interest receivables classified by staging of credit risk

As at 31 March 2022 and 31 December 2021, the balances of loan and interest receivables (excluding policy loans and interest receivables), classified by staging of credit risk were as follows:

(Unit: Thousand baht)

	Consolidated and separate financial statements									
		31 March 2022								
	Mortga	ge loans	Othe	r loans		Total				
Staging of credit risk	Principal	Interest	Principal	Interest receivables	Principal	Interest	Total			
Stage 1 - Loans without a significant										
increase of credit risk	50,195	•	60	-	50,255	-	50,255			
Stage 2 - Loans with significant increase	s									
of credit risk	16,186	594	-	-	16,186	594	16,780			
Stage 3 - Credit impairment loans	473,155	70,291	-		473,155	70,291	543,446			
Total	539,536	70,885	60	•	539,596	70,885	610,481			
Less: Allowance for expected credit										
losses	(241,754)	(29,795)			(241,754)	(29,795)	(271,549)			
Loans and interest receivables - net	297,782	41,090	60	· <u>-</u>	297,842	41,090	338,932			

	Consolidated and separate financial statements								
		31 December 2021							
	Mortga	ge loans	Other loans		Total				
		Interest		Interest		Interest			
Staging of credit risk	Principal	receivables	Principal	receivables	Principal	receivables	Total		
Stage 1 - Loans without a significant									
increase of credit risk	51,742	-	58	-	51,800	-	51,800		
Stage 2 - Loans with significant increases	3								
of credit risk	17,927	594	-	-	17,927	594	18,521		
Stage 3 - Credit impairment loans	503,439	64,578	-	÷	503,439	64,578	568,017		
Total	573,108	65,172	58	-	573,166	65,172	638,338		
Less: Allowance for expected credit									
losses	(262,133)	(29,486)		<u>-</u>	(262,133)	(29,486)	(291,619)		
Loans and interest receivables - net	310,975	35,686	58	-	311,033	35,686	346,719		

#### 9. Investment in a subsidiary

As at 31 March 2022 and 31 December 2021, detail of investment in a subsidiary, as presented in the separate financial statements, was as follows:

									(Unit;	Thousand bahl)
	Type of	Country of	Issued a	nd paid-up					Carrying :	value under
Company's name	business	incorporation	share	e capitai	Shareholdi	ng percenlage	C	ost	equity	melhod
			31 March	31 December	31 March	31 December	31 March	31 December	31 March	31 December
			2022	2021	2022	2021	2022	2021	2022	2021
					(%)	(%)				
Phillip Insurance Broker	Non-life insurance	Thailand								
Company Limited	proker		5,000	5,000	99.88	99.88	4,994	4,994	5,323	5,197
Total investment in a sut	ostdiary						4,994	4,994	5,323	5,197

The Company recognised share of profit or loss from investment in a subsidiary in its separate statements under the equity method, which was based on the subsidiary's financial statements, prepared by the management but not yet reviewed or audited by its auditor.

#### 10. Leases

The Company has lease contracts for various items used in its operations. Leases generally have lease terms between 2 - 3 years.

#### 10.1 Right-of-use assets

	(Unit: Thousand baht)	
	Consolidated and separate	
	financial statements	
	For the three-month period ended 31 March 2022	
	Leased buildings	
Net book value as at 1 January 2022	44,468	
Cancelled during the period	(12,329)	
Depreciation for the period	(6,134)	
Net book value as at 31 March 2022	26,005	

#### 10.2 Lease liabilities

(Unit: Thousand baht)

(Unit: Thousand baht)

25,127

255,318

(27,467)

227,851

#### Consolidated and separate

21,577

237,778

(27,215)

210,563

	financial statements			
	31 March 2022	31 December 2021		
Amounts of lease payments	31,202	50,136		
Less: Deferred interest expenses	(856)	(1,685)		
Lease liabilities	30,346	48,451		
Less: Current portion	(19,458)	(27,946)		
Lease liabilities - net of current portion	10,888	. 20,505		

#### 11. Other assets

Others

Total

Less: Allowance for

impairment

Other assets - net

As at 31 March 2022 and 31 December 2021, other assets consisted of the following items:

	Consolidated fir	nancial statements	Separate fina	incial statements
	31 March 2022	31 December 2021	31 March 2022	31 December 2021
Rental deposits	6,790	6,983	6,790	6,983
Agents and brokers				
receivables	23,584	32,838	23,584	32,838
Other receivables	151,352	151,278	151,494	151,421
Withholding taxes	29,240	27,410	29,240	27,410
Receivables from sales of				
investments	bo:	6,446	-	6,446
Receivable from the Legal		•		
Executive Department	5,093	5,093	5,093	5,093

25,749

255,797

(27,467)

228,330

22,135

238,194

(27,215)

210,979

#### 12. Insurance contract liabilities

(Unit: Thousand baht)

	Consolidated and separate financial statements						
	31 March 2022			31 December 2021			
	Insurance	Reinsurance		Insurance	Reinsurance		
	liabilities	of liabilities	Net	llabilities	of liabilities	Net	
Long-term insurance policy reserves	8,709,221	-	8,709,221	9,310,423	-	9,310,423	
Loss reserves							
Claims incurred and reported	71,866	(203)	71,663	94,937	(269)	94,668	
Claims incurred but not yet reported	315,592	(47)	315,545	211,551	(123)	211,428	
Premium reserves							
Unearned premium reserves	361,123	(8,262)	352,861	360,577	(7,910)	352,667	
Unexpired risk reserves	63,037	(243)	62,794	60,775	(299)	60,476	
Unpaid policy benefits	58,600	-	58,600	50,349	-	50,349	
Other insurance liabilities	566,106	*	566,106	569,963	-	569,963	
Total	10,145,545	(8,755)	10,136,790	10,658,575	(8,601)	10,649,974	

#### 12.1 Long-term insurance policy reserves

(Unit: Thousand baht)

# Consolidated and separate

	financial statements				
	For the three-month	For the			
	period ended	year ended			
	31 March 2022	31 December 2021			
Balances - beginning of the periods	9,310,423	9,766,755			
Insurance policy reserves increased for new					
businesses and inforce policies	396,767	1,660,988			
Insurance policy reserves released from death,					
benefit paid, lapse and surrender	(239,872)	(1,036,547)			
Change in insurance policy reserves as a result of					
assumption changes	(735,466)	(1,006,466)			
Changes in insurance policy reserves as a result					
of experience adjustments	(22,631)	(74,307)			
Balances - end of the periods	8,709,221	9,310,423			

# 12.2 Short-term insurance policy reserves

#### (a) Loss reserves

(Unit: Thousand baht)
Consolidated and separate

	financial statements				
	For the three-month	For the			
	period ended	year ended			
	31 March 2022	31 December 2021			
Balances - beginning of the periods Claims incurred in the current periods Changes in loss reserves from the prior year Claims paid during the periods	306,488 486,699 (147,989) (257,740)	415,990 1,702,437 (25,169) (1,786,770)			
Balances - end of the periods	387,458	306,488			

# (b) Unearned premium reserves

Consolidated and separate	
financial statements	

	For the three-month	For the	
	period ended	year ended	
	31 March 2022	31 December 2021	
Balances - beginning of the periods	360,577	474 570	
Premium written during the periods	225,402	471,579 1,527,067	
Premium earned during the periods	(224,856)	(1,638,069)	
Balances - end of the periods	361,123	360,577	

#### (c) Unexpired risk reserves

(Unit: Thousand baht)

#### Consolidated and separate

financial	statements
IIIIGEIOIGI	Ottatomonio

	(111-11)-141(-141141)-141			
	For the three-month	For the		
	period ended	year ended		
	31 March 2022	31 December 2021		
Balances - beginning of the periods	421,352	586,551		
Estimated claims	269,799	1,875,419		
Risk expired during the periods	(266,991)	(2,040,618)		
Balances - end of the periods	424,160	421,352		

As at 31 March 2022 and 31 December 2021, the Company has an excess of unexpired risk reserves from unearned premium reserves net of reinsurance by Baht 62.8 million and Baht 60.5 million, respectively. During the three-month period ended 31 March 2022, the Company was already recognised a reversal of such reserves of Baht 2.3 million in profit or loss.

#### 12.3 Unpaid policy benefits

(Unit: Thousand baht)

#### Consolidated and separate

#### financial statements

	31 March 2022	31 December 2021	
Death benefits	8,203	5,435	
Maturity payments	18,246	18,940	
Surrender	966	834	
Benefit payments under policies	761	866	
Others	30,424	24,274	
Total unpaid policy benefits	58,600	50,349	

#### 12.4 Other insurance liabilities

(Unit: Thousand baht)

#### Consolidated and separate

	financial	financial statements			
	31 March 2022	31 December 2021			
Deposits of the insured	535,812	532,706			
Others	30,294	37,257			
Total other insurance liabilities	566,106	569,963			

#### 13. Reinsurance payables

As at 31 March 2022 and 31 December 2021, the Company had reinsurance payables classified by type of liabilities as follows:

(Unit: Thousand baht)

Consolidated and separate

	financial statements			
	31 March 2022	31 December 2021		
Outward premium payables	12,857	12,633		
Total due to reinsurers	12,857	12,633		

#### 14. Deferred tax liabilities and income tax benefits

#### 14.1 Deferred tax liabilities

As at 31 March 2022 and 31 December 2021, deferred tax liabilities consisted of tax effects arose from the following temporary difference items:

			(Unit: T	housand Baht)	
	Consolidated and separate financial statements				
			Changes in defer	red tax liabilities	
			for the three-mont	h periods ended	
	31 March	31 December	31 Ma	arch	
	2022	2021	2022	2021	
Deferred tax liabilities arose from:					
Unrealised gains on available-for-					
sale investments measured at		•			
fair value through other					
comprehensive income	162,104	162,570	466	(7,457)	
Unrealised gains on trading					
investments measured at fair					
value through profit or loss	22,165	38,221	16,056	734	
Total deferred tax liabilities	184,269	200,791			
Total changes			16,522	(6,723)	
Recognition of changes in:					
- Profit or loss			16,056	734	
- Other comprehensive income			466	(7,457)	
Total changes			16,522	(6,723)	

As at 31 March 2022 and 31 December 2021, the Group had tax-deductible temporary differences and unused tax losses for which the Group did not record deferred tax assets since the management has already assessed and believes that it will not have sufficient taxable profit in the future to utilise such deductible temporary differences and unused tax losses before they expire. Those tax-deductible temporary differences and unused tax losses items are as bellows:

(Unit: Thousand Baht)

	Consolidated financial statements		Separate financ	cial statements	
	31 March	31 December	31 March	31 December	
	2022	2021	2022	2021	
Employee benefit obligations	51,508	57,601	51,508	57,601	
Loss reserves	387,208	306,096	387,208	306,096	
Unexpired risk reserves	62,794	60,476	62,794	60,476	
Leases	4,772	4,414	4,772	4,414	
Allowance for impairment	20,101	18,872	20,101	18,872	
Expected credit losses	373,605	392,657	373,605	392,657	
Tax losses brought forward no					
longer than five fiscal years	184,030	829,945	184,030	829,945	
Total	1,084,018	1,670,061	1,084,018	1,670,061	

#### 14.2 Income tax benefits (expenses)

Current income taxes:
Corporate income tax for

**Deferred income taxes:**Relating to origination and reversal of temporary

the periods

differences

loss

Income tax benefits

recognised in profit or

Income tax benefits (expenses) for the three-month periods ended 31 March 2022 and 2021 were made up as follows:

(Unit: Thousand baht) Consolidated financial statements Separate financial statements For the three-month For the three-month periods ended 31 March periods ended 31 March 2022 2021 2022 2021 734 16,056 734 16,056 16,056 734 16,056 734

Reconciliations between income tax benefits and the product of accounting loss for the three-month periods ended 31 March 2022 and 2021 and the applicable tax rate were as follows:

	Consolidated financial statements		Separate financial statements	
	For the three-month		For the three-month	
	periods ended	31 March	periods ended 31 March	
	2022	2021	2022	2021
Accounting gain before income tax				
revenues	506,946	888,785	506,946	888,785
Applicable tax rate	20%	20%	20%	20%
Amount of income taxes at the				
applicable tax rate	(101,389)	(177,757)	(101,389)	(177,757)
Net tax effect on revenues or				
expenses that are not taxable or				
not deductible in determining				
taxable profits	989	963	989	963
Temporary differences (reversal),				
which are not recognised as				
deferred tax assets	(12,727)	8,951	(12,727)	8,951
Taxes on carried forward loss which				
were expected not to be utilised				
and not recorded as deferred tax				
assets but utilised during the				
period	129,183	168,577	129,183	168,577
Income tax benefits recognised in				
profit or loss	16,056	734	16,056	734

The amounts of income taxes relating to each component of other comprehensive income (loss) For the three-month periods ended 31 March 2022 and 2021 were as follows:

(Unit: Thousand baht) Consolidated and separate financial statements For the three-month periods ended 31 March 2022 2021 Income taxes relating to: Available-for-sale investments measured at fair value through other comprehensive income (10,960)(4,662)losses on revaluation during the years (20)(23)Recognition of expected credit losses in profit or loss 1,050 (246)Recognition (reversal) of impairment loss in profit or loss 2,473 5,397 Recognition of gains on sales in profit or loss 466 (7,457)Income taxes reported in other comprehensive income (loss)

#### 15. Other liabilities

As at 31 March 2022 and 31 December 2021, other liabilities consisted of the following items:

			(Unit:	Thousand baht)
	Consolida	ted financial	Separate financial	
	statements		statements	
	31 March 31 December 2022 2021		31 March	31 December
			2022	2021
Accrued commission and brokerage expenses	41,163	68,311	41,163	68,311
Deposits from agents	71,564	78,551	71,564	78,551
Accrued operating expenses	21,070	33,130	20,474	32,029
Payables from purchases of investments	-	8,013		8,013
Others	6,591	7,108	6,591	7,108
Total other liabilities	140,388	195,113	139,792	194,012

#### 16. Expected credit losses

			(Unit: <sup>-</sup>	Thousand baht)		
	Consolidated		Separate			
	financial statements  For the three-month periods ended 31 March		financial statements			
			For the three-month		For the thre	e-month
			periods ended	31 March		
	2022	2021	2022	2021		
Cash and cash equivalents	6	(98)	6	(98)		
Accrued investment income	898	888	898	888		
Investments in securities	114	98	114	98		
Loans and interest receivables	(20,070)	14,911	(20,070)	14,911		
Total	(19,052)	15,799	(19,052)	15,799		

#### 17. Earnings per share

Basic earnings per share is calculated by dividing net profit attributable to the Company's shareholders (excluding other comprehensive income (loss)) by the weighted average number of ordinary shares in issue during the periods.

Earnings per share for the three-month periods ended 31 March 2022 and 2021 were determined as follows:

	Consolidated		Separate	
_	financial statements		financial statements	
	For the three	e-month	For the three-month periods ended 31 March	
_	periods ended	31 March		
	2022 2021		2022	2021
Net profit attributable to the				
Company's shareholders				
(Thousand baht)	523,002	889,519	523,002	889,519
Weighted average number of				
ordinary shares				
(Thousand shares)	957,500	929,586	957,500	929,586
Basis earning per share				
Earnings per share (Baht/share)	0,55	0,96	0.55	0.96

#### 18. Related party transactions

#### 18.1 Type of relationship

The relationship between the Company and its related parties, who have significant business transactions with the Company, are summarised below.

Name of related parties Type of relationship	
Phillip Life Company Limited	Parent company
Phillip Insurance Broker Company Limited	Subsidiary
Phillip Securities (Thailand) Public Company Limited	Having common directors
Key management personnel	Persons having authority and responsibility
	for planning, directing and controlling the
	activities of the entity, directly or indirectly,
	including any director (whether executive or
	otherwise) of the Company.

#### 18.2 Significant business transactions with related parties

The Company had significant business transactions with its related parties. Such transactions, which have been concluded on commercial terms and bases agreed upon in the ordinary course of business between the Company and those parties, were as follows:

	Consolidated and financial state	,	·
	For the three		
	periods ended	3 I March	
	2022	2021	Pricing policy
Related parties			
Expenses			
Securities management fee	1,218	1,036	Contract rates or agreed-upon rates
Commission expenses	395	608	Contract rates or agreed-upon rates

#### 18.3 Outstanding balances with related parties

As at 31 March 2022 and 31 December 2021, the outstanding balances between the Company and its related parties were as follows:

			(Unit	:: Thousand Baht)
	Conso	lidated	Sep	parate
	financial statements		financial statements financial statemen	
	31 March	31 December	31 March	31 December
	2022	2021	2022	2021
Subsidiary				
Assets				
Receivables from related parties	-		142	142
Related companies				
Assets				
Premium receivables	33	33	33	33
Liabilities				
Accrued securities management fee	1,218	1,216	1,218	1,216

#### 18.4 Directors' and key management's remunerations

The Group had employee benefit expenses incurred in relation to its directors and key management as below.

	(Unit: Thousand Baht)		
	Consolidated and separate		
	financial statements		
	For the three-month		
	periods ended 31 March		
	2022	2021	
Short-term employee benefits	1,151	765	
Long-term employee benefits	12	35	
Total	1,163	800	

#### 19. Litigations

As at 31 March 2022 and 31 December 2021, the Company had outstanding litigation cases whereby the Company has been sued by its policyholders claiming for benefits under the insurance contracts for the amount of Baht 5.03 million and Baht 5.03 million, respectively. The judgment of the cases has not yet been finalised and the Company's management expects that the Company will win the cases and there will be no payments as a result of such claims. Therefore, the Company recorded no provision of liabilities on those litigation cases.

#### 20. Fair values of financial instruments

As at 31 March 2022 and 31 December 2021, the Group had financial assets and liabilities that were measured or disclosed at fair value using different levels of inputs as follows:

		Consolidal	ted financial st	atements	
		3	1 March 2022		
	Fair value			Carrying	
	Level 1	Level 2	Level 3	Total	value
Financial assets measured at fair values					
Trading investments measured at fair value through					
profit or loss					
Domestic unit trusts	-	3,449,222	-	3,449,222	3,449,222
Foreign unit trusts	-	663,964	-	663,964	663,964
Available-for-sale investments measured at fair					
value through other comprehensive income					
Government and state enterprise securities	**	2,007,700	-	2,007,700	2,007,700
Private sector debt securities		2,730,321	80,920	2,811,241	2,811,241
Domestic common stocks	430,840	-	6,642	437,482	437,482
Foreign common stocks	2,159,675	-	-	2,159,675	2,159,675
Domestic unit trusts	837,708	•	-	837,708	837,708
Foreign unit trusts	266,052	-	-	266,052	266,052
Financial assets for which fair values were					
disclosed					
Cash and cash equivalents	582,885	-	-	582,885	582,885
Accrued investment income	-	45,107	-	45,107	45,107
Held-to-maturity investments measured at amortised					
cost					
Deposits at financial institutions with maturity					
periods of longer than 3 months	-	20,317	-	20,317	20,317
Policy loans and interest receivables	-	-	611,345	611,345	547,532
Mortgage loans, other loans and interest receivables	-	-	508,453	508,453	338,932
Financial liabilities for which fair values were					
disclosed					
Lease liabilities	-	-	30,346	30,346	30,346

Consolidated	financial	statements
Collabilidated	unancia	Statements

		31	December 202	11	
	Fair value			Carrying	
	Level 1	Level 2	Level 3	Total	value
Financial assets measured at fair values					
Trading investments measured at fair value through					
profit or loss					
Domestic unit trusts	-	3,457,912	-	3,457,912	3,457,912
Foreign unit trusts	-	662,619	•	662,619	662,619
Available-for-sale investments measured at fair					
value through other comprehensive income					
Government and state enterprise securities	_	2,026,196	-	2,026,196	2,026,196
Private sector debt securities	-	2,786,458	80,920	2,867,378	2,867,378
Domestic common stocks	499,383	-	6,446	505,829	505,829
Foreign common stocks	2,060,621	-		2,060,621	2,060,621
Domestic unit trusts	818,191		-	818,191	818,191
Foreign unit trusts	260,623	-	-	260,623	260,623
Financial assets for which fair values were					
disclosed					
Cash and cash equivalents	516,914	-		516,914	516,914
Accrued investment income	-	36,674	-	36,674	36,674
Investments measured at amortised cost					
Deposits at financial institutions with a maturity					
period of longer than 3 months	-	20,170		20,170	20,170
Policy loans and Interest receivables		-	629,471	629,471	554,841
Mortgage loans, other loans and interest receivables	-	-	564,796	564,796	346,719
Financial liabilities for which fair values were					
disclosed					
Lease liabilities	-	-	48,451	48,451	48,451

Separate	financial	statements
----------	-----------	------------

		3	1 March 2022		
	Fair value			Carrying	
	Level 1	Level 2	Level 3	Total	value
Financial assets measured at fair values					
Trading investments measured at fair value fair value					
through profit or loss					
Domestic unit trusts		3,449,222	-	3,449,222	3,449,222
Foreign unit trusts	-	663,964	•	663,964	663,964
Available-for-sale investments measured at fair value					
through other comprehensive income					
Government and state enterprise securities	-	2,007,700	-	2,007,700	2,007,700
Private sector debt securities	-	2,730,321	80,920	2,811,241	2,811,241
Domestic common stocks	430,840	-	6,642	437,482	437,482
Foreign common stocks	2,159,675	-	-	2,159,675	2,159,675
Domestic unit trusts	837,708	-	-	837,708	837,708
Foreign unit trusts	266,052	-	-	266,052	266,052
Financial assets for which fair values were					
disclosed					
Cash and cash equivalents	577,376	-	-	577,376	577,376
Accrued investment income	-	45,107	-	45,107	45,107
Held-to-maturity investments measured					
at amortised cost					
Deposits at financial institutions with maturity					
periods of longer than 3 months	~	20,317	-	20,317	20,317
Policy loans and interest receivables	-		611,345	611,345	547,532
Mortgage loans, other loans and interest receivables	-	-	508,453	508,453	338,932
Financial liabilities for which fair values were					
disclosed					
Lease liabilities	**	-	30,346	30,346	30,346

(Unit: Thousand Baht)

Separate financial statements	
-------------------------------	--

•	31 December 2021				
	Fair value			Carrying	
	Level 1	Level 2	Level 3	Total	value
Financial assets measured at fair values	<del> </del>				
Trading investments measured at fair value fair value					
through profit or loss					
Domestic unit trusts	-	3,457,912	-	3,457,912	3,457,912
Foreign unit trusts	•	662,619	-	662,619	662,619
Available-for-sale investments measured at fair value					
through other comprehensive income					
Government and state enterprise securities	-	2,026,196	-	2,026,196	2,026,196
Private sector debt securities	-	2,786,458	80,920	2,867,378	2,867,378
Domestic common stocks	499,383	-	6,446	505,829	505,829
Foreign common stocks	2,060,621	-	-	2,060,621	2,060,621
Domestic unit trusts	818,191	-	-	818,191	818,191
Foreign unit trusts	260,623	-	-	260,623	260,623
Financial assets for which fair values were					
disclosed					
Cash and cash equivalents	511,089		-	511,089	511,089
Accrued investment income	-	36,674	-	36,674	36,674
Investments measured at amortised cost					
Deposits at financial institutions with a maturity					
period of longer than 3 months	**	20,170	-	20,170	20,170
Policy loans and interest receivables	-	-	629,471	629,471	554,841
Mortgage loans, other loans and interest receivables		-	564,796	564,796	346,719
Financial liabilities for which fair values were					
disclosed					
Lease liabilities	J	-	48,451	48,451	48,451

The methods and assumptions used by the Group in estimating the fair value of financial instruments are as follows:

- (a) The fair values of financial assets having short-term maturity, which are cash and cash equivalent, short-term deposits at financial institutes and accrued investment income, are estimated to approximate their carrying values.
- (b) Investments in debts securities are determined for fair values using the yield curve as announced by the Thai Bond Market Association.

- (c) Investment in equity securities are determined for fair values according to market prices or using the net asset value per unit as announced by the fund managers. In case of non-marketable equity securities, the fair value is generally determined using generally accepted pricing model or approximated to their net book values if the fair value cannot be reliably estimated.
- (d) The fair value of policy loans is estimated from the present value of cash flows discounted by zero coupon bonds.
- (e) The fair value of mortgaged loans is estimated from the present value of cash flows discounted by an average retail lending rates of 5 commercial banks.
- (f) The fair value of lease liabilities is approximated to their carrying values due to carrying an approximate market rate.

During the periods, there were no transfers within the fair value hierarchy.

Reconciliation of fair value measurements of equity financial assets, categorised within Level 3 of the fair value hierarchy, were presented below:

	(Unit: Thousand baht)
	Consolidated and separate
	financial statements
Balance as of 1 January 2022	6,446
Unrealised gains recognised in other comprehensive income	196
Balance as of 31 March 2022	6,642

#### 21. Approval of interim financial information

This interim financial information was authorised for issue by the Company's authorised director on 11 May 2022.